Articles
31.07.2019
Commercial patient access scheme

In England, to gain a positive recommendation for use within the NHS from NICE, pharmaceutical produ...

Read more
News
08.07.2019
Cancer drug receives NHS approval

A targeted drug has been accepted for routine use on the NHS in England for some adults with untreat...

Read more
Articles
27.06.2019
Joint pricing assessment in Europe

By joining together, countries can combine their resources to potentially increase the efficiency of...

Read more
Publications
20.06.2019
eLearning Training Programme

Pharmaceutical pricing and market access is the crucial challenge for successful product launch toda...

Read more
Articles
29.05.2019
What are precision medicines

What is the future of precision medicine in the EU? The field of precision medicine is a complex are...

Read more
Articles
28.05.2019
NICE scientific advice re Brexit

NICE will continue to offer joint advice with the Medicines and Healthcare products Regulatory Agenc...

Read more
News
30.04.2019
How pharmacist biosimilar substitution would work

The law provides a legal framework for the automatic substitution of biosimilars at the level of the...

Read more
News
10.04.2019
The Orkambi blame game

The deadlock between Vertex and NHS over the cystic fibrosis drug Orkambi was played out in a parlia...

Read more
News
08.04.2019
UK pharma negotiating choppy seas during Brexit

The ABPI is working closely with the Department of Health and Social Care, NHS England and NICE to e...

Read more
News
02.04.2019
Kymriah - a tale of two indications

NICE was the first EU HTA body to provide their assessment of Kymriah for ALL, publishing their opin...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.